Skip to main content

Kaligia Biosciences has begun clinical tests with its Rapid Biofluid Analyzer utilizing saliva to detect COVID-19 in just three minutes.

The technology was originally developed to find a less invasive way for people with diabetes to test their glucose levels. With the onset of the virus, Kaligia has adopted the methodology and machine learning to provide a more effective option to quickly test patients. Clinical trials have begun this week with local healthcare providers.

Unlike other tests which analyze samples with six-inch nasal swabs, Kaligia’s Rapid Biofluid Analyzer 2 points a laser at the collected saliva sample to reveal the underlying chemical components and then draws on machine learning to identify positive and negative results.

Full Article on Tampa Bay Times

Leave a Reply